Coming Soon

Season 1: Network Effects
Unlock exponential growth
Master the 16 network effects
20 years of insights in one class

Investing Profile

Niall O’Donnell

InvestorVC

Managing Director at RiverVest Venture Partners

Photo of Niall O’Donnell, Managing Director at RiverVest

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RiverVest Managing Director
$100K - $1M
$100K
10
$184.4M
CompanyStageDateRound SizeTotal Raised
Glycomine
Series BJun 2021$35M
$35M
Co-investors: Jim Trenkle (Sanofi Ventures), Bali Muralidhar (Abingworth)
Reneo Pharmaceuticals
Series BDec 2020$95M
Series AMay 2019$50M
$150M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Bali Muralidhar (Abingworth)
Mirum Pharmaceuticals
Series ANov 2018$120M
$120M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Patrick Heron (Frazier Healthcare Partners), Jonathan Leff (Deerfield Management)
Amplyx Pharmaceuticals
Series BNov 2015$41M
$41M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Alex Kahn (Generation Ventures)
Otonomy
Series DApr 2014$49M
Series CSep 2013$46M
Series BAug 2010$39M
$140M
Co-investors: Brian Dovey (Domain Associates), Bill Harrington (Osage University Partners), John McKearn (RiverVest), Jay Lichter (Avalon Ventures), Peter Bisgaard (Pivotal bioVenture Partners), Heather Preston (Pivotal bioVenture Partners)
Lumena Pharmaceuticals
Series BMar 2014$45M
Series AMay 2013$23M
$68M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), John McKearn (RiverVest)